Advantest Co. (OTCMKTS:ATEYY – Get Free Report) was the recipient of a large decrease in short interest in November. As of November 15th, there was short interest totalling 3,800 shares, a decrease of 86.5% from the October 31st total of 28,200 shares. Based on an average daily trading volume, of 225,100 shares, the days-to-cover ratio is currently 0.0 days.
Advantest Price Performance
Shares of ATEYY traded down $1.75 during trading hours on Wednesday, reaching $55.30. 58,727 shares of the company traded hands, compared to its average volume of 215,407. The stock has a market capitalization of $40.81 billion, a PE ratio of 60.05 and a beta of 1.45. The stock has a fifty day simple moving average of $54.03 and a 200 day simple moving average of $44.53. Advantest has a fifty-two week low of $28.32 and a fifty-two week high of $64.95. The company has a quick ratio of 1.58, a current ratio of 3.04 and a debt-to-equity ratio of 0.17.
Advantest (OTCMKTS:ATEYY – Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.41 earnings per share (EPS) for the quarter. The company had revenue of $1.28 billion for the quarter. Advantest had a net margin of 17.67% and a return on equity of 24.47%. As a group, research analysts predict that Advantest will post 1.16 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Read Our Latest Analysis on ATEYY
Advantest Company Profile
Advantest Corporation manufactures and sells semiconductors, component test system products, and mechatronics related products in Japan, the Americas, Europe, and Asia. The company operates through three segments: Semiconductor and Component Test System; Mechatronics Related Business; and Services, Support and Others.
Featured Articles
- Five stocks we like better than Advantest
- Profitably Trade Stocks at 52-Week Highs
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- What is a Secondary Public Offering? What Investors Need to Know
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Advantest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advantest and related companies with MarketBeat.com's FREE daily email newsletter.